Abstracts tagged "Biologics"

Abstract Number: 1022 • 2013 ACR/ARHP Annual Meeting
Initiation Of Biologic Therapy: The Patient Perspective
Amir Goren¹, Susan C. Bolge², Duncan Brown³, Roxanne Meyer⁴ and Seth Ginsberg⁵, ¹Kantar Health, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Kantar Health, New york, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, NY, ⁵Creaky Joints, New York, NY
Background/Purpose: Current guidelines for the treatment of rheumatoid arthritis (RA) recommend that patients who are not adequately responding to treatment with disease modifying anti-rheumatic drugs…
Abstract Number: 363 • 2013 ACR/ARHP Annual Meeting
Comparing Myocardial Infarction Risks Associated With Biologics Of Varying Mechanisms Of Action Among Older RA Patients
Jeffrey R. Curtis¹, Huifeng Yun², Jie Zhang³, Fenglong Xie⁴, Lang Chen⁵, Emily Levitan², James Lewis⁶, Timothy Beukelman⁷, Kenneth G. Saag⁸ and Iris Navarro-Millan⁵, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Pennsylvania, Philadelphia, PA, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Anti-TNF biologics have been associated with a reduced risk for acute myocardial infarction (AMI) in some rheumatoid arthritis (RA) populations. The comparative risks for…
Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting
First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Frank Behrens¹, Mikkel Ostergaard², Rumen Stoilov³, Piotr Wiland⁴, Thomas W. Huizinga⁵, Vadym Y. Berenfus⁶, Paul-Peter Tak⁷, Stoyanka Vladeva⁸, Juergen Rech⁹, Andrea Rubbert-Roth¹⁰, Mariusz Korkosz¹¹, Dmitriy Rekalov¹², Igor A. Zupanets¹³, Bo J. Ejbjerg¹⁴, Jens Geiseler¹⁵, Julia Fresenius¹⁵, Roman P. Korolkiewicz¹⁶, Arndt J. Schottelius¹⁶ and Harald Burkhardt¹, ¹CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, ²Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, ⁸Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, ⁹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Internal Medicine I, University of Cologne, Cologne, Germany, ¹¹Malopolskie Centrum Medyczne, Krakow, Poland, ¹²Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹³Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, ¹⁴Slagelse Sygehus, Slagelse, Denmark, ¹⁵Asklepios Clinic Munich-Gauting, Gauting, Germany, ¹⁶Development, MorphoSys AG, Martinsried/Planegg, Germany
Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].